Close Menu

thyroid cancer

The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.

Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.

Pages